Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil

Clinical Transplantation

Volumn 19, Issue 2, 2005, Pages 199-206

  Arns, Wolfgang ^a   Breuer, Stephan ^a   Choudhury, Somesh ^b   Taccard, Guy ^b   Lee, James ^b   Binder, Vera ^b   Roettele, Jürgen ^b   Schmouder, Robert ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bioavailability; Enteric coated mycophenolate sodium; Mycophenolate mofetil; Mycophenolic acid; Myfortic

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY TRACT INFECTION;

ADULT; AGED; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG DELIVERY SYSTEMS; FEMALE; GLUCURONATES; GLUCURONIDES; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SAFETY; SOLUBILITY; TABLETS, ENTERIC-COATED; THERAPEUTIC EQUIVALENCY;

EID: 15844416494     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00318.x     Document Type: Article

References (33)

1. Denton MD, Magee CC, Sayegh MH. Immunosuppressive therapies in transplantation. Lancet 1999: 353: 1083.
2. Hedstrom L. IMP dehydrogenase: mechanism of action and inhibition. Curr Med Chem 1999: 6: 545.
3. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996: 10: 118.
4. Ransom JT. Mechanism of action of mycophenolate mofetil. Therap Drug Monit 1995: 17: 681.
5. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
6. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection on cadaveric renal transplantation. Transplantation 1996: 61: 1029.
7. Sollinger HW for the US Renal Transplant Mycophenolate Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
8. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998: 66: 507.
9. Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999: 68: 261.
10. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996: 36: 315.
11. Brunet M, Martorell J, Oppenheimer F et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transplant Int 2000: 13 (Suppl. 1): S301.
12. Ito R, Nogami T, Yasuda T et al. Pharmacokinetics of mycophenolic acid in healthy human volunteers. J Med Soc Japan 1982: 29: 412.
13. Hebert MF, Ascher NL, Lake JR et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999: 67: 707.
14. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000: 47: 215.
15. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: etiology, incidence and management. Drug Saf 2001: 24: 645.
16. Mourad M, Malaise J, Chaib Eddour D et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001 47: 88.
17. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
18. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on outcomes in renal transplantation. Clin Transplant 2003: 17: 200.
19. Kaplan B, Meier-Kriesche HU, Jacobs MG et al. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis 1999: 34: 65.
20. Gallagher H, Andrews PA. Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link? Drug Saf 2001: 24: 405.
21. Cattaneo D, Gaspari F, Ferrari S et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001: 15: 402.
22. Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998: 64: 672.
23. Sugioka N, Chen SH, Hayashida K et al. Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. Biopharm Drug Dispos 1995: 16: 591.
24. Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001: 33: 3238.
25. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7: 161.
26. Shipkova M, Strassburg CP, Braun F et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001: 132: 1027.
27. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001: 33: 3241.
28. Mahalati K, Kahan BD. Pharmacological surrogates of allograft outcome. Ann Transplant 2000: 5: 14.
29. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab 2002: 3: 275.
30. Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997: 5: 225.
31. Hübner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999: 21: 536.
32. Filler G, Lepage N, Delisle B, Mai I. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 2201: 23: 514.
33. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002: 62: 1060.